DEPDC1基因在上皮性卵巢肿瘤中的表达及其临床意义
发布时间：2018-10-22 14:51
【摘要】：背景:卵巢癌(Ovarian Cancer,OC)在妇科常见三大恶性肿瘤中预后最差、死亡率最高、五年存活率徘徊在30-40%。上皮性卵巢癌(Epithelial Ovarian Cancer,EOC)又是卵巢恶性肿瘤中最常见的病理类型。CA125、HE4等肿瘤标志物结合经阴道超声检查等卵巢癌的早期筛查措施已经应用于临床多年,但仍有大量卵巢癌患者发现时已经处于晚期。手术、化疗和PARP抑制剂靶向治疗是卵巢癌的主要治疗手段,CA125、HE4仍是目前确切应用于临床的两种可以用于监测上皮性卵巢癌复发和治疗效果的生化指标,尽管其敏感性还远不能满足临床需求。DEP domain containing 1(DEPDC1)是一个最新发现的奇特的肿瘤相关的基因,此基因已证明在人的多种类型的恶性肿瘤中表达上调并且与肿瘤分化有关。DEPDC1是在细胞周期中能够调节有丝分裂相关进程的基因,从而参与肿瘤的发生与发展。目前此基因在卵巢肿瘤中的研究仍为空白。方法:本研究选取自2013年1月到2016年4月在烟台毓璜顶医院妇科住院治疗的:47例卵巢恶性肿瘤组织、15例交界性卵巢肿瘤组织、12例卵巢良性肿瘤组织、18例因良性子宫肌瘤手术的正常卵巢组织,(共计92例)进行石蜡包埋切片。所有病例均由青岛大学附属烟台毓璜顶医院病理科同一组医生做出病理诊断,并由组内经验丰富的病理专家复片确诊。研究检验DEPDC1基因的表达主要采取免疫组织化学染色的方法,并采用Western Blot进行蛋白定量验证。结果:DEPDC1基因在卵巢交界及恶性组(包含交界肿瘤)中的表达率为98.39%,但在卵巢正常及良性组只有10.00%的DEPDC1高表达(P0.05)。分析实验结果发现DEPDC1基因在卵巢交界性及恶性肿瘤中高表达,在正常和良性卵巢组织中低表达。然而DEPDC1基因表达水平与卵巢上皮性恶性肿瘤的FIGO分期及病理类型并没有明显的相关性。同时,研究发现CA125水平的升高和DEPDC1基因上调有一定的相关性(r=0.393)。结论:DEPDC1基因在卵巢上皮性恶性肿瘤及交界性卵巢肿瘤中的表达水平显著高于正常及良性组织。在今后临床工作及实验研究中,DEPDC1基因有望对卵巢上皮性恶性肿瘤的筛查、早期诊断、预后分析提供有价值的临床指导。
[Abstract]:Background: ovarian cancer (Ovarian Cancer,OC) has the worst prognosis and the highest mortality among the three common gynecological malignancies, and the five-year survival rate hovers at 30-40. Epithelial ovarian cancer (Epithelial Ovarian Cancer,EOC) is also the most common pathological type of ovarian malignancy. Early screening for ovarian cancer, such as CA125,HE4 and transvaginal ultrasound, has been used in clinical practice for many years. However, there are still a large number of ovarian cancer patients found at the time of late. Surgery, chemotherapy and targeted therapy with PARP inhibitors are the main treatments for ovarian cancer. CA125,HE4 is still the two biochemical markers that can be used to monitor the recurrence and therapeutic effect of epithelial ovarian cancer. Although its sensitivity is far from satisfying clinical needs,. DEP domain containing 1 (DEPDC1) is a novel tumor-related gene, This gene has been proved to be up-regulated and related to tumor differentiation in various types of malignant tumors. DEPDC1 is a gene that regulates mitotic processes in cell cycle and thus participates in the occurrence and development of tumors. At present, the study of this gene in ovarian tumors is still blank. Methods: from January 2013 to April 2016, 47 cases of malignant ovarian tissues, 15 cases of borderline ovarian tumors, 12 cases of benign ovarian tumors and 18 cases of benign ovarian tumors were selected. Paraffin embedded sections were performed in 92 cases of normal ovarian tissue of uterine leiomyoma. All cases were diagnosed by the same group of doctors in the Department of Pathology of Yantai Yuding Hospital affiliated to Qingdao University. The expression of DEPDC1 gene was assayed by immunohistochemical staining and protein quantification by Western Blot. Results: the expression rate of DEPDC1 gene was 98.39% in ovarian borderline and malignant group (including borderline tumor), but only 10.00% of DEPDC1 was overexpressed in normal and benign ovarian group (P0.05). The results showed that DEPDC1 gene was highly expressed in ovarian borderline and malignant tumors, and low in normal and benign ovarian tissues. However, there was no significant correlation between the expression of DEPDC1 gene and the FIGO stage and pathological type of ovarian epithelial tumor. At the same time, there was a correlation between the increase of CA125 level and the up-regulation of DEPDC1 gene (r = 0.393). Conclusion: the expression of DEPDC1 gene in epithelial ovarian neoplasms and borderline ovarian tumors is significantly higher than that in normal and benign tissues. In the future clinical work and experimental research, DEPDC1 gene is expected to provide valuable clinical guidance for screening, early diagnosis and prognostic analysis of ovarian epithelial malignant tumors.
【学位授予单位】：青岛大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.31
本文编号：2287474
[Abstract]:Background: ovarian cancer (Ovarian Cancer,OC) has the worst prognosis and the highest mortality among the three common gynecological malignancies, and the five-year survival rate hovers at 30-40. Epithelial ovarian cancer (Epithelial Ovarian Cancer,EOC) is also the most common pathological type of ovarian malignancy. Early screening for ovarian cancer, such as CA125,HE4 and transvaginal ultrasound, has been used in clinical practice for many years. However, there are still a large number of ovarian cancer patients found at the time of late. Surgery, chemotherapy and targeted therapy with PARP inhibitors are the main treatments for ovarian cancer. CA125,HE4 is still the two biochemical markers that can be used to monitor the recurrence and therapeutic effect of epithelial ovarian cancer. Although its sensitivity is far from satisfying clinical needs,. DEP domain containing 1 (DEPDC1) is a novel tumor-related gene, This gene has been proved to be up-regulated and related to tumor differentiation in various types of malignant tumors. DEPDC1 is a gene that regulates mitotic processes in cell cycle and thus participates in the occurrence and development of tumors. At present, the study of this gene in ovarian tumors is still blank. Methods: from January 2013 to April 2016, 47 cases of malignant ovarian tissues, 15 cases of borderline ovarian tumors, 12 cases of benign ovarian tumors and 18 cases of benign ovarian tumors were selected. Paraffin embedded sections were performed in 92 cases of normal ovarian tissue of uterine leiomyoma. All cases were diagnosed by the same group of doctors in the Department of Pathology of Yantai Yuding Hospital affiliated to Qingdao University. The expression of DEPDC1 gene was assayed by immunohistochemical staining and protein quantification by Western Blot. Results: the expression rate of DEPDC1 gene was 98.39% in ovarian borderline and malignant group (including borderline tumor), but only 10.00% of DEPDC1 was overexpressed in normal and benign ovarian group (P0.05). The results showed that DEPDC1 gene was highly expressed in ovarian borderline and malignant tumors, and low in normal and benign ovarian tissues. However, there was no significant correlation between the expression of DEPDC1 gene and the FIGO stage and pathological type of ovarian epithelial tumor. At the same time, there was a correlation between the increase of CA125 level and the up-regulation of DEPDC1 gene (r = 0.393). Conclusion: the expression of DEPDC1 gene in epithelial ovarian neoplasms and borderline ovarian tumors is significantly higher than that in normal and benign tissues. In the future clinical work and experimental research, DEPDC1 gene is expected to provide valuable clinical guidance for screening, early diagnosis and prognostic analysis of ovarian epithelial malignant tumors.
【学位授予单位】：青岛大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.31
【参考文献】
相关期刊论文 前2条
1 李崧;田红旗;;卵巢癌分子靶向治疗研究进展[J];中国新药与临床杂志;2016年11期
2 卢仁泉;郭林;沈烨红;;HE4在卵巢癌诊治中的临床应用评价[J];中国癌症杂志;2010年09期
，本文编号：2287474
本文链接：https://www.wllwen.com/kejilunwen/jiyingongcheng/2287474.html
最近更新
教材专著
